Clinical and hematological profile of patients with philadelphia-negative myeloproliferative neoplasms: First report from the Ecuadorian registry - PubMed
3 hours ago
- #JAK2 mutation
- #Myeloproliferative neoplasms
- #Ecuadorian registry
- Study explores clinical and epidemiological profiles of 111 Ecuadorian patients with Philadelphia-negative myeloproliferative neoplasms (MPNs).
- Polycythemia vera was the most common subtype (45.9%), followed by essential thrombocythemia (42.3%) and primary myelofibrosis (9%).
- JAK2 V617F mutation was most prevalent in essential thrombocythemia (53.2%) and polycythemia vera (41.2%).
- Hydroxyurea was the most widely used treatment, prescribed to 77% of patients.
- Disease progression to myelofibrosis occurred in some cases, and two cases progressed to acute myeloid leukemia.
- Survival rates varied, with some patients achieving up to 19 years of survival.
- Results suggest a homogeneous epidemiological profile in Latin America and highlight the need for more multicenter studies.